Literature DB >> 16267409

Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in caucasians.

Terrance P O'Hanlon1, Danielle Mercatante Carrick, Frank C Arnett, John D Reveille, Mary Carrington, Xiaojiang Gao, Chester V Oddis, Penelope A Morel, James D Malley, Karen Malley, Jonathan Dreyfuss, Ejaz A Shamim, Lisa G Rider, Stephen J Chanock, Charles B Foster, Thomas Bunch, Paul H Plotz, Lori A Love, Frederick W Miller.   

Abstract

The idiopathic inflammatory myopathies (IIM) are systemic connective tissue diseases in which autoimmune pathology is suspected to promote chronic muscle inflammation and weakness. We have performed low to high resolution genotyping to characterize the allelic profiles of HLA-A, -B, -Cw, -DRB1, and -DQA1 loci in a large population of North American Caucasian patients with IIM representing the major clinicopathologic groups (n = 571). We confirmed that alleles of the 8.1 ancestral haplotype were important risk markers for the development of IIM, and a random forests classification analysis suggested that within this haplotype, HLA-B*0801, DRB1*0301 and/ or closely linked genes are the principal HLA risk factors. In addition, we identified several novel HLA factors associated distinctly with 1 or more clinicopathologic groups of IIM. The DQA1*0201 allele and associated peptide-binding motif (KLPLFHRL) were exclusive protective factors for the CD8+ T cell-mediated IIM forms of polymyositis (PM) and inclusion body myositis (IBM) (pc < 0.005). In contrast, HLA-A*68 alleles were significant risk factors for dermatomyositis (DM) (pc = 0.0021), a distinct clinical group thought to involve a humorally mediated immunopathology. While the DQA1*0301 allele was detected as a possible risk factor for IIM, PM, and DM patients (p < 0.05), DQA1*03 alleles were protective factors for IBM (pc = 0.0002). Myositis associated with malignancies was the most distinctive group of IIM wherein HLA Class I alleles were the only identifiable susceptibility factors and a shared HLA-Cw peptide-binding motif (AGSHTLQWM) conferred significant risk (pc = 0.019). Together, these data suggest that HLA susceptibility markers distinguish different myositis phenotypes with divergent pathogenetic mechanisms. These variations in associated HLA polymorphisms may reflect responses to unique environmental triggers resulting in the tissue pathospecificity and distinct clinicopathologic syndromes of the IIM.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16267409     DOI: 10.1097/01.md.0000189818.63141.8c

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  30 in total

1.  An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity.

Authors:  Emily C Baechler; Jason W Bauer; Catherine A Slattery; Ward A Ortmann; Karl J Espe; Jill Novitzke; Steven R Ytterberg; Peter K Gregersen; Timothy W Behrens; Ann M Reed
Journal:  Mol Med       Date:  2007 Jan-Feb       Impact factor: 6.354

Review 2.  Sporadic inclusion body myositis: variability in prevalence and phenotype and influence of the MHC.

Authors:  F L Mastaglia
Journal:  Acta Myol       Date:  2009-10

3.  Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy.

Authors:  Andrew L Mammen; Daniel Gaudet; Diane Brisson; Lisa Christopher-Stine; Thomas E Lloyd; Mary S Leffell; Andrea A Zachary
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-08       Impact factor: 4.794

Review 4.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.

Authors:  Angela B Robinson; Ann M Reed
Journal:  Nat Rev Rheumatol       Date:  2011-09-27       Impact factor: 20.543

5.  Associations of HLA-A, HLA-B and HLA-C alleles frequency with prevalence of herpes simplex virus infections and diseases across global populations: implication for the development of an universal CD8+ T-cell epitope-based vaccine.

Authors:  Sarah Samandary; Hédia Kridane-Miledi; Jacqueline S Sandoval; Zareen Choudhury; Francina Langa-Vives; Doran Spencer; Aziz A Chentoufi; François A Lemonnier; Lbachir BenMohamed
Journal:  Hum Immunol       Date:  2014-05-04       Impact factor: 2.850

6.  Dermatomyositis: immunological landscape, biomarkers, and potential candidate drugs.

Authors:  Ruxue Yin; Gangjian Wang; Lei Zhang; Tianfang Li; Shengyun Liu
Journal:  Clin Rheumatol       Date:  2021-01-03       Impact factor: 2.980

7.  Interferon-gamma and interleukin-4 gene polymorphisms in Caucasian idiopathic inflammatory myopathy patients in UK.

Authors:  Hector Chinoy; Fiona Salway; Sally John; Noreen Fertig; Brian D Tait; Chester V Oddis; William E R Ollier; Robert G Cooper
Journal:  Ann Rheum Dis       Date:  2007-04-03       Impact factor: 19.103

8.  The effect of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis.

Authors:  Adam Schiffenbauer; Sara Faghihi-Kashani; Terrence P O'Hanlon; Willy A Flegel; Sharon D Adams; Ira N Targoff; Chester V Oddis; Steven R Ytterberg; Rohit Aggarwal; Lisa Christopher-Stine; Ejaz A Shamim; Paul F Dellaripa; Sonye K Danoff; Andrew L Mammen; Frederick W Miller
Journal:  Semin Arthritis Rheum       Date:  2018-02-14       Impact factor: 5.532

9.  Genetic risk and protective factors for the idiopathic inflammatory myopathies.

Authors:  Terrance P O'Hanlon; Frederick W Miller
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

10.  Seasonal birth patterns in myositis subgroups suggest an etiologic role of early environmental exposures.

Authors:  Leora J Vegosen; Clarice R Weinberg; Terrance P O'Hanlon; Ira N Targoff; Frederick W Miller; Lisa G Rider
Journal:  Arthritis Rheum       Date:  2007-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.